RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Following brain scan changes before Parkinson’s develops

Researchers use repeated specialised scans to study changes in people with signs that may precede a Parkinson’s diagnosis.

Testing a treatment or activity · Study reference: NCT07265596

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported actual date)
2023-10-30
Main measurements finished (planned)
2027-12
Study finished (planned)
2027-12

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Age 18 years and over · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: 1. A Prodromal PD participant, over the age of 18, confirmed as eligible to proceed to PPMI Clinical Baseline visit. 2. Able to provide informed consent. 3. Male or Female (females must meet additional criteria specified below as applicable) * Females must be of non-childbearing potential or using a highly effective method of birth control 14 days prior to until at least 24 hours after injection of 18F-AV-133 * Non-childbearing potential is defined as a female that must be either postmenopausal (no menses for at least 12 months prior to PET scan) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy). * Highly effective method of birth control is defined as practicing at least one of the following: A birth control method that results in a less than 1% per year failure rate when used consistently and correctly, such as oral contraceptives for at least 3 months prior to injection, an intrauterine device (IUD) for at least 2 months prior to injection, or barrier methods, e.g., diaphragm or combination condom and spermicide. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable. * Females of childbearing potential must not be pregnant, breastfeeding or lactating. * Includes a negative urine pregnancy test prior to injection of 18F-AV-133 on day of PET scan. Exclusion Criteria: 1. Received any of the following medications that might interfere with 18F- AV-133 PET imaging: tetrabenazine (TBZ) or methylphenidate, reserpine, or amphetamine derivative, within 1 month prior to the Baseline 18F-AV-133 injection. 2. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.
Full study name & original research details

Official study title

Early Longitudinal Imaging in the Parkinson's Progression Markers Initiative Using [18F] AV-133 (PPMI AV-133 Prodromal Imaging)

Short title used by the registry

Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

Original description

The study is a longitudinal, multi-center study to assess progression of \[18F\] AV-133 imaging in Prodromal PD participants. Participants will be followed for up to 24 months. Approximately 100 Prodromal participants will be recruited from up to 10 sites. Participants will be comprehensively assessed at baseline and follow up. Participants will undergo imaging assessments with \[18F\] AV-133 and clinical (motor, neuropsychiatric, cognitive and imaging and biomarker) assessments (conducted under the PPMI Clinical protocol).

Further description from the registry

The Parkinson's Progression Marker Initiative (PPMI) is an observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide the necessary tools to enhance the likelihood of success of therapeutics studies to slow PD progression (ClinicalTrials.gov Identifier: NCT01141023). A key focus of PPMI is to identify biomarkers during the period when PD neurodegeneration is already present, but symptoms of PD have not yet occurred. This prodromal cohort would enable us to investigate PD biomarker signatures prior to onset of typical symptoms of PD. The study is a longitudinal, multi-center study to assess progression of \[18F\]AV-133 imaging in Prodromal PD participants. The PPMI 015 study will enroll participants from the PPMI Clinical (002) study. Participants will be followed annually for up to 24 months. Approximately 100 Prodromal participants will be recruited from up to 10 sites. Participants will be comprehensively assessed at baseline and follow up. Participants will undergo \[18F\]AV-133 PET imaging targeting the vesicular monoamine transporter. All participants will undergo an initial \[18F\]AV-133 PET imaging scan at baseline with repeat imaging at 12 months and 24 months.

Conditions reported: Prodromal Parkinsons Disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
[18F] AV-133 PET Imaging
Phases
PHASE2
Sponsor
Michael J. Fox Foundation for Parkinson's Research
Start date reported by registry
2023-10-30 (actual)

Registry updated: 2025-12-05 · Status last verified by the registry submitter: 2025-11

Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Lianne Ramia · 203-590-5600 · LRamia1@indd.org

Jessica Dimos · 203-590-5600 · jdimos@indd.org

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Institute for Neurodegenerative Disorders

New Haven, Connecticut, United States

Recruiting

Mackenzee George Clinical Research Coordinator II · 475-318-8248 · mgeorge@xingimaging.com

Amy Ruimerman Lead Clinical Research Nurse, LPN · 475-318-8208 · aruimerman@xingimaging.com

Neha Prakash, MBBS

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Recruiting

PPMI Call Center · 877-525-7764

Nabila Dahodwala, MD

Toronto Western Hospital

Toronto, Ontario, Canada

Not yet recruiting

PPMI Call Center · 877-525-7764

Connie Marras

Philipps-University of Marburg

Hessen, Germany

Not yet recruiting

Elisabeth Sittig · sittig@med.uni-marburg.de

Wolfgang Oertel

Tel Aviv Sourasky Medical Center

Tel Aviv, Israel

Not yet recruiting

Anat Mirelman · Bsc972-3-697-3014 · anatmi@tlvmc.gov.il

Roy Alcalay, MD

Radboud University

Nijmegen, Gelderland, Netherlands

Not yet recruiting

Yara Krasowski · info@onderzoek-parkinson.nl

Bastiaan Bloem, MD

Queen Mary University of London

London, Britain, United Kingdom

Recruiting

Cristina Simonet · 44-02078823379 · c.simonet@qmul.ac.uk

Cristina Simonet, MD

Alastair Noyce, MD

Newcastle University

Newcastle upon Tyne, Tyne and Wear, United Kingdom

Recruiting

Victoria Foster · +441912081197 · victoria.foster@ncl.ac.uk

Nicola Pavese

David Ledingham

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.